Prostate Cancer Screening Test Downgraded

The US Preventative Services Task Force (UPSTF) recently downgraded the prostate-specific antigen (PSA) test to class D, meaning that the potential harms of the test outweigh the benefits, as it often gives false positives.

Many organizations vary in recommendation of who should get a PSA test. Some prostate cancers do not need treatment as it can e a slow-growing cancer that never spreads beyond the prostate gland.

The only other prostate screening test, the digital rectal exam (DRE), is also infamously known as ineffective.

Prostate cancer is the most commonly diagnosed cancer in American men. Therefore, men who have symptoms of prostate cancer (trouble urinating, blood in urine, blood in semen, leg swelling, pelvic discomfort) should discuss screening and treatment options with a physician as to whether PSA testing is an appropriate measure to take.